In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

Möller T, Krug O, Thevis M

Rapid communications in mass spectrometry : RCM1 Apr 2026Cited by 2 (Europe PMC)

PMID41588687PMCIDPMC12835572DOI10.1002/rcm.70039PepBankPUB-41588687

Summary

RationaleEstrogen-related receptor (ERR) agonists such as the drug candidates SLU-PP-332 and SLU-PP-915 are currently being investigated as exercise mimetics, given their ability to trigger human physiological processes similar to those initiated by actual physical activity. This capability prompted the consideration of these compounds as drugs potentially relevant for sports drug testing programs.MethodsThe two pan-ERR agonists SLU-PP-332 and SLU-PP-915 were characterized using liquid chromatography-high resolution (tandem) mass spectrometry (LC-HRMS/MS). Furthermore, the in vitro metabolic transformation products of both compounds prepared by means of human liver S9 fraction (S9 fraction) and human liver microsomes (HLMs) were analyzed. In addition, selected metabolites of SLU-PP-915 were synthesized and their structures were analyzed by nuclear magnetic resonance (NMR) spectroscopy.ResultsA total of nine metabolites were identified for SLU-PP-332, consisting of six Phase-I metabolites and three Phase-II conjugates. Conversely, the analysis of SLU-PP-915 yielded only Phase-I transformation products, with a total of seven metabolites identified. In both cases, an in-depth structural elucidation was conducted to obtain a comprehensive overview of the detected metabolites. Furthermore, three metabolites of SLU-PP-915 were confirmed through chemical synthesis and NMR.ConclusionThe results obtained in this study gave an in-depth view into the analysis and in vitro metabolism of the newly developed pan-ERR agonists SLU-PP-332 and SLU-PP-915. This may help to uncover the illicit use of these novel compounds as potential performance-enhancing substances.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking SLU-PP-332.

01LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver preparations, SLU‑PP‑332 yielded nine metabolites.
In plain wordsIn lab tests, SLU‑PP‑332 yielded nine metabolites in human liver preparations.
Peptide
SLU-PP-332
Outcome
Not applicableIn vitro metabolite count
Study
humann: not reported in source
Human liver S9 fraction and microsomes
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
A total of nine metabolites were identified for SLU-PP-332, consisting of six Phase-I metabolites and three Phase-II conjugates.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the in vitro metabolic transformation products of both compounds prepared by means of human liver S9 fraction (S9 fraction) and human liver microsomes (HLMs) were analyzed.
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Show in the study text Report a problemFND-4158868701
02LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver preparations, SLU‑PP‑332 yielded six Phase-I metabolites.
In plain wordsIn lab tests, SLU‑PP‑332 yielded six Phase-I metabolites.
Peptide
SLU-PP-332
Outcome
Not applicablePhase-I metabolite count
Study
humann: not reported in source
Human liver S9 fraction and microsomes
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
A total of nine metabolites were identified for SLU-PP-332, consisting of six Phase-I metabolites and three Phase-II conjugates.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the in vitro metabolic transformation products of both compounds prepared by means of human liver S9 fraction (S9 fraction) and human liver microsomes (HLMs) were analyzed.
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Show in the study text Report a problemFND-4158868702
03LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver preparations, SLU‑PP‑332 yielded three Phase-II conjugates.
In plain wordsIn lab tests, SLU‑PP‑332 yielded three Phase-II conjugates.
Peptide
SLU-PP-332
Outcome
Not applicablePhase-II conjugate count
Study
humann: not reported in source
Human liver S9 fraction and microsomes
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
A total of nine metabolites were identified for SLU-PP-332, consisting of six Phase-I metabolites and three Phase-II conjugates.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the in vitro metabolic transformation products of both compounds prepared by means of human liver S9 fraction (S9 fraction) and human liver microsomes (HLMs) were analyzed.
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Show in the study text Report a problemFND-4158868703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.